MSB 3.21% $1.13 mesoblast limited

Ann: Partnership For Allogeneic Cell-based Cancer Immunotherapies, page-28

  1. 15,643 Posts.
    lightbulb Created with Sketch. 5711
    Well said @benelong ... thanks for putting this into context:

    they chose MSB because it's world's best. Best in product. Best in production. They don't take second best. They would not allow their opportunity to produce ground breaking research to be handicapped by an inferior partner.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.